LN Met 50 Tablet ER is a combination antihypertensive medication containing Cilnidipine 10mg and Metoprolol Succinate 50mg. Cilnidipine is a calcium channel blocker that inhibits the influx of calcium ions through L-type and N-type calcium channels, leading to vasodilation and reduction in peripheral vascular resistance. Metoprolol Succinate is a selective beta-1 adrenergic receptor blocker that decreases heart rate, myocardial contractility, and cardiac output, thereby lowering blood pressure and reducing myocardial oxygen demand. This extended-release formulation ensures a sustained therapeutic effect, promoting better blood pressure control over 24 hours with once-daily dosing. LN Met 50 Tablet ER is indicated for the management of essential hypertension, particularly in patients who require dual therapy for optimal blood pressure control. The combination of cilnidipine and metoprolol offers complementary mechanisms of action, improving efficacy while minimizing adverse effects commonly associated with higher doses of monotherapy. Caution is advised in patients with bradycardia, heart block, or severe hepatic impairment. Regular monitoring of blood pressure, heart rate, and renal function is recommended during therapy. LN Met 50 Tablet ER should be used under medical supervision, with dose adjustments based on clinical response and tolerability.